- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06270706
En fas 1-studie av PLN-101095 hos vuxna med avancerade eller metastaserande solida tumörer
En fas 1a/1b multicenter, öppen dosupptrappning/expansionsstudie för att utvärdera säkerhet, tolerabilitet, farmakokinetik och preliminära bevis för antitumöraktivitet av PLN-101095 som monoterapi och i kombination med Pembrolizumab hos vuxna deltagare med fasta tumörer med avancerad eller metastaserad tumör Som har sjukdomsprogression medan de tar Pembrolizumab
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory [primary resistance]) or relapsed [secondary resistance]) after at least 3 months from the start of treatment with pembrolizumab.
The study will consist of 2 main parts:
- Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration
- Part 2: Dose-expansion cohorts using Simon's 2-stage design
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Pliant Therapeutics Medical Monitor
- Telefonnummer: clintrials@pliantrx.com
- E-post: clintrials@pliantrx.com
Studieorter
-
-
Connecticut
-
New Haven, Connecticut, Förenta staterna, 06511
- Avslutad
- Yale University
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 20007
- Rekrytering
- Georgetown University Medical Center
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30322
- Rekrytering
- Winship Cancer Institute of Emory University
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
Michigan
-
Grand Rapids, Michigan, Förenta staterna, 49546
- Rekrytering
- South Texas Accelerated Research Therapeutics (START)
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63110
- Rekrytering
- Washington University Medicine
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
New Jersey
-
East Brunswick, New Jersey, Förenta staterna, 08816
- Rekrytering
- START New Jersey
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
New Brunswick, New Jersey, Förenta staterna, 08901
- Rekrytering
- Rutgers Cancer Institute of New Jersey
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
New York
-
Lake Success, New York, Förenta staterna, 11042
- Rekrytering
- START New York Long Island LLC
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
North Carolina
-
Wilson, North Carolina, Förenta staterna, 27893
- Rekrytering
- Carolina Cancer Research Center
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
South Dakota
-
Sioux Falls, South Dakota, Förenta staterna, 57105
- Rekrytering
- Avera Medical Group
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Rekrytering
- Tennessee Oncology
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
Texas
-
Austin, Texas, Förenta staterna, 78758
- Rekrytering
- NEXT Austin
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
Fort Worth, Texas, Förenta staterna, 76104
- Rekrytering
- START Center for Clinical Research
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- University of Texas MD Anderson Cancer Center
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
Houston, Texas, Förenta staterna, 77054
- Rekrytering
- NEXT Houston
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
San Antonio, Texas, Förenta staterna, 78229
- Rekrytering
- UT Health San Antonio's Mays Cancer Center
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
Utah
-
West Valley City, Utah, Förenta staterna, 84119
- Rekrytering
- START Mountain Region
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- Rekrytering
- Inova Schar Cancer Institute
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
Fairfax, Virginia, Förenta staterna, 22031
- Rekrytering
- NEXT Virginia
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
Washington
-
Edmonds, Washington, Förenta staterna, 98026
- Rekrytering
- Swedish Cancer Institute Medical Oncology
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
-
-
Barcelona
-
Barcelona, Barcelona, Spanien, 08023
- Rekrytering
- Hospital Universitari Quirónsalud (NEXT Barcelona)
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
Barcelona, Barcelona, Spanien, 08023
- Rekrytering
- START Barcelona - Hospital HM Nou Delfos
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
Barcelona, Barcelona, Spanien, 08035
- Rekrytering
- Hospital Universitari Vall d'Hebron - VHIO
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
La Rioja
-
Logroño, La Rioja, Spanien, 26006
- Rekrytering
- START Center for Cancer Research - La Rioja
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
Madrid
-
Madrid, Madrid, Spanien, 28040
- Rekrytering
- START Madrid - Hospital Universitario Fundación Jiménez Díaz
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
Madrid, Madrid, Spanien, 28050
- Rekrytering
- START Madrid - Centro Integral Oncológico Clara Campal
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
Pozuelo de Alarcón
-
Madrid, Pozuelo de Alarcón, Spanien, 28223
- Rekrytering
- University Hospital Quironsalud Madrid (NEXT Madrid)
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-post: clintrials@pliantrx.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Has histologically or cytologically confirmed advanced or metastatic solid tumor
- Have received ≥12 weeks of continuous anti-PD-1 or anti-PD-L1 treatment administered as monotherapy or in combination with other anticancer therapies
- Have demonstrated documented prior clinical benefit, defined as CR or PR at any time during treatment, or SD lasting ≥6 months (Part 2 only)
- Must have subsequently developed radiographic disease progression while receiving anti-PD-1 or anti-PD-L1 treatment or within ≤12 weeks after the last dose of such treatment
- At least 1 measurable lesion, as defined by RECIST v1.1
- Estimated survival of ≥3 months
- Have adequate bone marrow and organ function.
- A female participant is eligible to participate if she is not pregnant, not breastfeeding
Exclusion Criteria:
- Any immune-related medical conditions that would put participants at greater risk when receiving pembrolizumab
- Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
- Has received prior radiotherapy within 2 weeks for palliative bone-directed therapy and 4 weeks for all other radiotherapy
- Has undergone major surgery within 4 weeks prior to the first dose of study treatment or has not adequately recovered from surgery or related complications
- Has a diagnosis of immunodeficiency or use of systemic steroids >10 mg/day
- Has an active autoimmune disease that has required systemic treatment in the past 2 years
- Has known active CNS metastases (brain and/or leptomeningeal metastases)
- Has significant cardiac disease
- Has an active infection requiring systemic therapy (including uncontrolled HIV, Hepatitis B and C)
- Has received a live or live-attenuated vaccine within 30 days or a non-live vaccine within 7 days prior to the first dose of PLN-101095
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part 1 Dose Escalation - 250 mg BID
Cohort 1 PLN-101095 250 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Experimentell: Part 1 Dose Escalation - 500 mg BID
PLN-101095 500 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Experimentell: Part 1 Dose Escalation - 1000 mg BID
PLN-101095 1000 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Experimentell: Part 1 Dose Escalation - 1000 mg TID
PLN-101095 1000 mg TID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Experimentell: Part 1 Dose Escalation - 2000 mg BID
PLN-101095 2000 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Experimentell: Part 2 Dose Expansion - NSCLC
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Non-small cell lung cancer (NSCLC) |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Experimentell: Part 2 Dose Expansion - ccRCC
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Clear cell renal cell carcinoma (ccRCC) |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Experimentell: Part 2 Dose Expansion - TMB-high solid tumors
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Tumor mutational burden (TMB)-high solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
Tidsram: First dose to 35 days
|
Number of participants with a Dose Limiting Toxicity (DLT) defined as toxicities that meet predefined severity criteria, assess as having a suspected relationship to study drug, unrelated to disease, inter-current illness, or concomitant medications. |
First dose to 35 days
|
|
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
Tidsram: Day 1 until 16 weeks after end of study treatment regimen
|
Proportion of participants with treatment-emergent adverse events and serious adverse events. |
Day 1 until 16 weeks after end of study treatment regimen
|
|
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tidsram: First dose to disease progression or death from any cause, whichever occurs first.
|
Proportion of participants achieving confirmed iPR or iCR per iRECIST Version 1.1. |
First dose to disease progression or death from any cause, whichever occurs first.
|
|
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tidsram: First dose to disease progression or death from any cause, whichever occurs first.
|
Proportion of participants who maintain disease control (iCR, iPR or iSD) per iRECIST Version 1.1. |
First dose to disease progression or death from any cause, whichever occurs first.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Tidsram: Day 14, 0 to up to 12 hours
|
Maximum drug concentration (Cmax) |
Day 14, 0 to up to 12 hours
|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Tidsram: Day 14, 0 to up to 12 hours
|
Time to Cmax (Tmax) |
Day 14, 0 to up to 12 hours
|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Tidsram: Day 14, 0 to up to 12 hours
|
Area under the concentration-time curve (AUC0-τ) |
Day 14, 0 to up to 12 hours
|
|
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tidsram: First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
|
Duration of response (DOR) for objective responders |
First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
|
|
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tidsram: First dose to progression or death from any cause, whichever occurs first
|
Time on treatment (TOT) for objective responders |
First dose to progression or death from any cause, whichever occurs first
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Pliant Therapeutics Medical Monitor, Pliant Therapeutics, Inc.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
- Uroteliala karcinom
- Immunterapi
- Pembrolizumab
- Melanom
- Kolorektal cancer
- Endometriecancer
- Icke-småcellig lungcancer (NSCLC)
- Kolangiokarcinom
- Avancerad solida tumörcancer
- Gallblåsa
- Ovarialt karcinom
- Trippel negativ bröstcancer (TNBC)
- Analt karcinom
- Clear Cell njurcellscancer (CCRCC)
- Gallvägs cancer (BTC)
- Huvud- och halscancer (HNSCC)
- Tumor mutational burden (TMB)-höga tumörer
- TMB-låga tumörer
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Sjukdomar i det endokrina systemet
- Patologiska processer
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Manliga urogenitala sjukdomar
- Njursjukdomar
- Urologiska sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Tarmsjukdomar
- Luftvägssjukdomar
- Neoplasmer efter histologisk typ
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Livmodersjukdomar
- Genitala sjukdomar, kvinnor
- Lungsjukdomar
- Neoplasmer i endokrina körtel
- Neoplasmer, körtel och epitel
- Adenocarcinom
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Kolonsjukdomar
- Neoplastiska processer
- Lungneoplasmer
- Ovariella sjukdomar
- Adnexala sjukdomar
- Genitala neoplasmer, hona
- Gonadal sjukdomar
- Hudsjukdomar
- Bröstsjukdomar
- Urologiska neoplasmer
- Carcinom
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Neoplasmer i njurarna
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Uterina neoplasmer
- Neuroendokrina tumörer
- Nevi och melanom
- Neoplasmer i huden
- Bröstneoplasmer
- Anus sjukdomar
- Rektal neoplasmer
- Patologiska tillstånd, tecken och symtom
- Hud- och bindvävssjukdomar
- Kolorektala neoplasmer
- Ovariella neoplasmer
- Neoplasma Metastas
- Karcinom, njurcell
- Karcinom, icke-småcellig lunga
- Kolangiokarcinom
- Melanom
- Trippelnegativa bröstneoplasmer
- Endometriella neoplasmer
- Karcinom, övergångscell
- Anus neoplasmer
- pembrolizumab
Andra studie-ID-nummer
- PLN-101095-ONC-101
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .